Skip to content

OBIPHAR: what changed

BE 0878.100.418NACE 47.730, Retail sale of pharmaceutical productsOther company

Position among the sector peers

What moved between 2024 and 2025

Net result for the year
-€1,220
2024 · €6,654-€7,874
Equity
€118,848
2024 · €120,068-€1,220
Cash
€118,717
2024 · €115,316+€3,401
Balance sheet total
€218,848
2024 · €120,068+€98,780

Largest movements

2024 to 2025
Assets
  • Intangible fixed assets +€93,333

    first reported in 2025, at €93,333

  • Cash +€3,401

    up €3,401 (+2.9%), from €115,316 to €118,717

    mainly Trade debts (+€100,000) and Depreciation (+€6,667)

Equity and liabilities
  • Trade debts +€100,000

    first reported in 2025, at €100,000

Income statement
  • Depreciation +€6,667

    first reported in 2025, at €6,667

  • Gross operating margin -€3,412

    down €3,412 (-35.0%), from €9,742 to €6,330

  • Taxes -€2,218

    no longer reported in 2025; in 2024 it stood at €2,218

Change in the result, 2024 to 2025

effect on the result

For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.

Result 2024 €6,654
Gross operating margin -€3,412
Depreciation -€6,667
Other operating charges -€13
Taxes +€2,218
Result 2025 -€1,220
raises the resultlowers the result

Derived cash bridge

cash 2024 to 2025

The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.

From operations +€103,401
Investment -€100,000
Financing €0
Cash 2024 €115,316
Net result for the year -€1,220
Depreciation +€6,667
Receivables within one year -€2,046
Trade debts +€100,000
Investment in fixed assets (net) -€100,000
Cash 2025 €118,717
brings cash intakes cash out
Every line side by side 30 lines
Line Code 2024 2025 Change %
Total assets 20/58 €120,068 €218,848 +€98,780 +82.3%
Fixed assets 21/28 - €93,333 +€93,333
Intangible fixed assets 21 - €93,333 +€93,333
Current assets 29/58 €120,068 €125,515 +€5,447 +4.5%
Amounts receivable within one year 40/41 €4,752 €6,798 +€2,046 +43.1%
Other amounts receivable 41 €4,752 €6,798 +€2,046 +43.1%
Cash at bank and in hand 54/58 €115,316 €118,717 +€3,401 +2.9%
Total equity and liabilities 10/49 €120,068 €218,848 +€98,780 +82.3%
Equity 10/15 €120,068 €118,848 -€1,220 -1.0%
Contributions 10/11 €100,000 €100,000 = 0.0%
Capital 10 €100,000 €100,000 = 0.0%
Issued capital 100 €100,000 €100,000 = 0.0%
Reserves 13 €4,399 €4,399 = 0.0%
Non-distributable reserves 130/1 €4,399 €4,399 = 0.0%
Legal reserve 130 €4,399 €4,399 = 0.0%
Profit (loss) carried forward 14 €15,669 €14,449 -€1,220 -7.8%
Amounts payable 17/49 - €100,000 +€100,000
Amounts payable within one year 42/48 - €100,000 +€100,000
Trade debts 44 - €100,000 +€100,000
Bills of exchange payable 441 - €100,000 +€100,000
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets 630 - €6,667 +€6,667
Other operating charges 640/8 €387 €400 +€13 +3.4%
Gross operating margin 9900 €9,742 €6,330 -€3,412 -35.0%
Operating profit (loss) 9901 €9,355 -€737 -€10,092
Financial charges 65/66B €483 €483 = 0.0%
Recurring financial charges 65 €483 €483 = 0.0%
Profit (loss) for the period before taxes 9903 €8,872 -€1,220 -€10,092
Income taxes 67/77 €2,218 - -€2,218
Profit (loss) for the period 9904 €6,654 -€1,220 -€7,874
Profit (loss) for the period to be appropriated 9905 €6,654 -€1,220 -€7,874

Value

latest balance sheet 31-12-2025 · indication, not a valuation or advice

Indicative value of the equity

Indication, not a valuation or advice
€25,014 to €29,918

Midpoint €27,058 · 50% capitalised earnings, 50% adjusted equity

Capitalisation rate 12% result over 3 years earnings weight 50%

Worked out with Checked's starting values, not your estimate and not market data. Change the assumptions: the value follows.

Adjusted equity €25,515
Capitalised earnings €24,514 to €34,320
Indication €25,014 to €29,918

Adjusted equity

balance sheet 31-12-2025
Equity (10/15)
€118,848
Intangible fixed assets (21)
-€93,333
Revaluation of assets
€0
Deferred tax on the revaluation
€0
Other adjustment
€0
Adjusted equity
€25,515

Capitalised earnings

net result for the year (9904)
2025
-€1,220
2024
€6,654
2023
€4,862
2022
€16,568
2021
€16,581
Average result
€3,432
Divided by the capitalisation rate
14% / 12% / 10%
Capitalised earnings
€24,514 / €28,600 / €34,320

Limits of the indication

  • Checked holds no market prices or comparable transactions.
  • Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
  • Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
  • The result is not corrected for the manager's pay. If the company pays less or more than a market salary, the capitalised earnings are too high or too low.
  • The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.

For a valuation to base a decision on, go to a company auditor or a certified accountant.

Calculation and sources

Source: filed annual accounts (NBB) and main activity (KBO). The movements compare the financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. The value is an indication, not a valuation or advice. Prepared on 17 November 2026 via checked.be.